Pharnext is the pioneer of a new R&D paradigm synergizing Pharma, Nutrition and Wellness. This approach, incubated by seasoned founders over 30 years, is applicable to virtually any human characteristic or trait (e.g. disease, ageing, aesthetics) and offers global care solutions integrating safe drugs and natural substances.

Since inception in 2007, Pharnext has successfully raised €50m financing, including €30m from high quality shareholders. Five major experimental programs are already in clinical development for neurodegenerative and metabolic diseases.